Dimai Hans Peter, Pietschmann Peter, Resch Heinrich, Preisinger Elisabeth, Fahrleitner-Pammer Astrid, Dobnig Harald, Klaushofer Klaus
Klinische Abteilung für Endokrinologie und Stoffwechsel, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Austria.
Wien Med Wochenschr. 2010 Dec;160(21-22):586-9. doi: 10.1007/s10354-010-0840-z.
The Austrian Society for Bone and Mineral Research routinely publishes evidence-based guidelines for the treatment of postmenopausal osteoporosis. The fully human monoclonal antibody denosumab (Prolia(®)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. Denosumab has been shown to reduce vertebral, non-vertebral,and hip-fracture risk effectively. Together with alendronate, risedronate, zoledronate, ibandronate, strontium ranelate, and raloxifene, denosumab constitutes an effective option in the treatment of postmenopausal osteoporosis.
奥地利骨与矿物质研究学会定期发布基于证据的绝经后骨质疏松症治疗指南。全人源单克隆抗体地诺单抗（Prolia®）最近已获欧洲药品管理局（EMEA）和美国食品药品监督管理局（FDA）批准用于治疗绝经后骨质疏松症。地诺单抗已被证明能有效降低椎体、非椎体和髋部骨折风险。与阿仑膦酸盐、利塞膦酸盐、唑来膦酸盐、伊班膦酸盐、雷奈酸锶和雷洛昔芬一样，地诺单抗是治疗绝经后骨质疏松症的有效选择。
